Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

Patient-derived xenografts and matched cell lines identify pharmacogenomic vulnerabilities in colorectal cancer

ABSTRACT: Patient-derived xenografts and matched cell lines identify pharmacogenomic vulnerabilities in colorectal cancer

PROVIDER: PRJEB33640 | ENA |

REPOSITORIES: ENA

ACCESS DATA

Json Xml

Dataset's files

Source:

			Action	DRS
	ERR13623140_1.fastq.gz	Fastqsanger.gz
	ERR13623140_2.fastq.gz	Fastqsanger.gz
	ERR13623141_1.fastq.gz	Fastqsanger.gz
	ERR13623141_2.fastq.gz	Fastqsanger.gz
	ERR13623142_1.fastq.gz	Fastqsanger.gz

Items per page:

1 - 5 of 224

Similar Datasets

Patient-Derived Xenografts and Matched Cell Lines Identify Pharmacogenomic Vulnerabilities in Colorectal Cancer.

Project description:PurposePatient-derived xenograft (PDX) models accurately recapitulate the tumor of origin in terms of histopathology, genomic landscape, and therapeutic response, but some limitations due to costs associated with their maintenance and restricted amenability for large-scale screenings still exist. To overcome these issues, we established a platform of 2D cell lines (xeno-cell lines, XL), derived from PDXs of colorectal cancer with matched patient germline gDNA available.Experimental designWhole-exome and transcriptome sequencing analyses were performed. Biomarkers of response and resistance to anti-HER therapy were annotated. Dependency on the WRN helicase gene was assessed in MSS, MSI-H, and MSI-like XLs using a reverse genetics functional approach.ResultsXLs recapitulated the entire spectrum of colorectal cancer transcriptional subtypes. Exome and RNA-seq analyses delineated several molecular biomarkers of response and resistance to EGFR and HER2 blockade. Genotype-driven responses observed in vitro in XLs were confirmed in vivo in the matched PDXs. MSI-H models were dependent upon WRN gene expression, while loss of WRN did not affect MSS XLs growth. Interestingly, one MSS XL with transcriptional MSI-like traits was sensitive to WRN depletion.ConclusionsThe XL platform represents a preclinical tool for functional gene validation and proof-of-concept studies to identify novel druggable vulnerabilities in colorectal cancer.

| S-EPMC7611232 | biostudies-literature

Expression data from patient and primary xenografts esophageal tumour samples

Project description:Microarrays were used to assess differences between 1) human tumours that did and did not engraft, 2) human tumours and their matched primary xenografts, 3) early and late passage primary xenografts and 4) small and large primary xenografts for a series of esophageal patient and primary xenograft tumours

2015-01-11 | GSE58870 | GEO

Thoracic patient-derived xenografts

Project description:Thoracic patient-derived xenografts

| PRJNA339191 | ENA

Chemogenomic profiling of breast cancer patient-derived xenografts reveals targetable vulnerabilities for difficult-to-treat tumors

Project description:Chemogenomic profiling of breast cancer patient-derived xenografts reveals targetable vulnerabilities for difficult-to-treat tumors

| PRJNA598222 | ENA

Patient-derived Human Breast Cancer Xenografts

Project description:Breast cancer research is hampered by difficulties in obtaining and studying primary human breast tissue, and by the lack of in vivo preclinical models that reflect patient tumor biology accurately. To overcome these limitations, we propagated a cohort of human breast tumors grown in the epithelium-free mammary fat pad of SCID/Beige and NOD/SCID/IL2γ-receptor null (NSG) mice, under a series of transplant conditions. Both models yielded stably transplantable xenografts at comparably high rates (~23% and ~19%, respectively). Of the conditions tested, xenograft take rate was highest in the presence of a low-dose estradiol pellet. Overall, 32 stably transplantable xenograft lines were established, representing unique 25 patients. Most tumors yielding xenografts were “triple-negative” (ER-PR-HER2+) (n=19). However, we established lines from three ER-PR-HER2+ tumors, one ER+PR-HER2-, one ER+PR+HER2- and one “triple-positive” (ER+PR+HER2+) tumor. Serially passaged xenografts show biological consistency with the tumor of origin, are phenotypic stability across multiple transplant generations at the histological, transcriptomic, proteomic, and genomic levels, and show comparable treatment responses. Xenografts representing 12 patients, including two ER+ lines, showed metastasis to the mouse lung. These models thus serve as a renewable, quality-controlled tissue resource for preclinical studies investigating treatment response and metastasis. The study was designed to determine how stable patient-derived xenografts are across multiple transplant generations in mice, and to determine how closely xenografts established with pre-treatment samples cluster with xenografts established with post-treatment samples. Overall, pre-treatment and post-treatment samples derived from the same patient cluster together, and multiple transplant generations of xenografts derived from an individual patient cluster together.

2013-05-30 | E-GEOD-46106 | biostudies-arrayexpress

Pharmacogenomic synthetic lethal screens reveal hidden vulnerabilities and new therapeutic approaches for treatment of NF1-associated tumor

Project description:Pharmacogenomic synthetic lethal screens reveal hidden vulnerabilities and new therapeutic approaches for treatment of NF1-associated tumor

| PRJNA1090069 | ENA

Proteomics of prostate cancer patient derived xenografts

Project description:A set of 17 prostate cancer patient-derived xenografts (PDX, Lin et al 2014, Cancer research) was analyzed by mass spectrometry-based proteomics to characterize the effects of castration in vivo, and the proteome differences between NEPC and prostate adenocarcinomas.

2019-09-11 | PXD009636 | Pride

Patient-derived Human Breast Cancer Xenografts

2013-05-30 | GSE46106 | GEO

Genomic analyses to identify metabolic vulnerabilities

Project description:Genomic analyses to identify metabolic vulnerabilities on PDX samples

| EGAS00001007244 | EGA

Acute Myeloid Leukemia (AML) patient xenografts

Project description:Acute Myeloid Leukemia (AML) patient xenografts

| PRJNA736604 | ENA